European Antibody Congress 2012 - list of video presentations & downloads

Chairman’s opening remarks › Dr Alain Beck, Head of Physico-Chemistry Department, Centre d'Immunologie Pierre Fabre

Biobetter antibodies in oncology in clinical development › Dr Steffen Goletz, Founder, CEO and CSO, Glycotope

Biopharmaceutical Characterization – mass spectrometric solutions for challenging analysis › Dr Catherine Evans, Business Development Manager Europe (Biopharma), Bruker Daltonics

Function-led antibody drug discovery: Solving the target deconvolution bottleneck › Jim Freeth, Associate, Retrogenix Ltd

Fully human, better behaved antibody drugs › Dr Robert Burns, Chief Executive Officer, 4-Antibody

Novartis Predictive tools for stabilization of therapeutic proteins › Dr Bernhard Helk, Global Executive Director, Technology Development, Novartis

Epitope characterization and crystal structure of GA101 provide insight into mechanism of action › Dr Christian Klein, Head Oncology Programs, Discovery Oncology, DTA Pharma Research and Early Development (PRED), Roche Glycart AG

Free or total therapeutic monoclonal antibody concentration monitoring › Dr Bing Kuang, Senior Principal Scientist, Pfizer

MeMo®, a Transgenic Mouse for the Discovery of Innovative Human Antibody Therapeutics › Dr Ton Logtenberg, CEO, Merus

Antibody characterization using unique enzymes in combination with mass spectrometry analysis › Dr Sarah Fredriksson, Chief Executive Officer, Genovis

Novel Systematic Approach for the Discovery of New Antibody Targets › Dr Anat Cohen-Dayag, President and CEO, Compugen

Antibody therapeutics development - state of the art › Dr Janice Reichert, Research Assistant Professor, Tufts Center for the Study of Drug Development

Novel antibody therapy Approach in Multiple Sclerosis and Schizophrenia › Dr Herve Perron, Chief Scientific Officer, GeNeuro

Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies › Prof Thomas Valerius, Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts University

CLIPS Technology meets GPCR: A New peptide based strategy for the generation of monoclonal Antibodies against GPCR’s › Dr Klaus Schwamborn, Chief Development Officer, Pepscan Therapeutics

The VIVA|SCREEN platform: a high throughput single B lymphocytes screening technology for the rapid discovery and production of fully human antigen-specific monoclonal antibodies › Dr Majid Mehtali, Managing Director and Chief Scientific Officer, Vivalis

Tetraspanin CD151 as a target for antibody-based cancer immunotherapy › Dr Jean-Francois Haeuw, Head of Biochemistry Department, Centre d’Immunologie Pierre Fabre

Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier › Dr Lois Lampson, Associate Professor of Neurosurgery, Brigham and Women's Hospital & Harvard Medical School

515H7 mAb, a new monoclonal antibody which blocks SDF-1/CXCR4 signaling for cancer therapy › Dr Christine Klinguer-Hamour, Oncology Project Leader, Centre d’Immunologie Pierre Fabre

Novel Development in immunotherapy and prophylaxis against influenza A Groups I and II › Dr Robert Friesen, VP Preclinical and Clinical Research, Crucell

Applying Tag-lite® to therapeutic antibody screening and characterization: A review of recent findings › Mr Stephane Martinez, Product Manager, Biotherapeutics, Cisbio Bioassays

Human monoclonal antibodies as adjunct therapies in infectious disease › Dr Michael Rudolf, Chief Scientific Officer, Kenta Biotech AG

Download MAbs Meeting Reports 

2011 Meeting Report - download it here

2010 Meeting Report - download it here

2009 Meeting Report - download it here